Addition of Rigosertib Fails to Improve Survival in Pancreatic Cancer

Share this content:
Rigosertib and gemcitabine combination did not improve survival in patients with treatment-naïve metastatic pancreatic adenocarcinoma.
Rigosertib and gemcitabine combination did not improve survival in patients with treatment-naïve metastatic pancreatic adenocarcinoma.

Compared with gemcitabine (GEM) monotherapy, rigosertib (RIG) and gemcitabine (GEM) combination did not improve survival in patients with treatment-naïve metastatic pancreatic adenocarcinoma, according to a recent study first published online this week in the journal Annals of Oncology.

The phase 2/3, two-arm international study had a total of 160 patients who were randomly assigned to RIG plus GEM or GEM alone. 

Results showed that there was no significant difference between the treatment arms for median overall survival where median overall survival was 6.1 months for RIG plus GEM and 6.4 months (HR= 1.24; 95% CI: 0.85, 1.81) for GEM.

The median progression-free survival was similar between arms as well, with 3.4 months (HR=0.96; 95% CI: 0.68, 1.36) in both arms. The partial response rate was slightly higher for RIG plus GEM (19%) compared with GEM alone (13%).

RELATED: Simple Clinical, Laboratory Parameters Predict Mortality in Pancreatic Adenocarcinoma

The most common grade 3 or higher adverse events with RIG plus GEM versus GEM alone, respectively, were neutropenia (8% vs. 6%), hyponatremia (17% vs. 4%), and anemia (8% vs. 4%).

The study suggests that RIG plus GEM is no better than GEM alone to improve survival in treatment-naïve metastatic pancreatic cancer. Moreover, the similar safety profile for rigosertib was seen in the previous trials.

Reference

  1. O'Neil BH, Scott AJ, Ma WW, et al. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol. 2015. [Epub ahead of print]. doi: 10.1093/annonc/mdv264.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters